Antiepileptogenic agents: how close are we?

Area of Science:

• Neurology
• Neuroscience
• Pharmacology

Background:

• Epilepsy affects approximately 4% of individuals lifetime.
• Epilepsy can be idiopathic, genetic, or acquired, with known causes accounting for one-third of cases.
• Current epilepsy management focuses on suppressing seizures after onset, rather than preventing the underlying process of epileptogenesis.

Purpose of the Study:

• To explore the potential of preventing epileptogenesis, the process of epilepsy development.
• To review laboratory models and drug candidates for antiepileptogenic effects.
• To evaluate the efficacy of existing and novel antiepileptic drugs in preventing epilepsy in humans.

Main Methods:

• Utilized laboratory models like kindling and chemical injections to study epileptogenesis.
• Reviewed studies on antiepileptic drugs (e.g., phenobarbital, valproate, levetiracetam) for antiepileptogenic potential.
• Analyzed clinical trial data and meta-analyses of drugs tested for preventing unprovoked seizures.

Main Results:

• Laboratory models and some drugs show promise for antiepileptogenic effects.
• Clinical trials of established antiepileptic drugs (phenobarbital, phenytoin, valproate, carbamazepine, diazepam) to prevent epileptogenesis yielded disappointing results.
• Meta-analyses indicated no significant reduction in unprovoked seizures; some drugs even showed a slight increase in seizure rates.

Conclusions:

• Current antiepileptic drugs have failed to demonstrate significant antiepileptogenic effects in human clinical trials.
• Novel drugs have not yet been evaluated for their ability to prevent epileptogenesis.
• Primary prevention of risk factors (e.g., head injury, stroke) is currently the most effective strategy to reduce epilepsy incidence.